Q2
DVA — Q2 2026 Financial Report Analysis
DaVita's Q2 2026 diluted EPS rose 56% to $4.02 on revenue up 5.2% to $3.55B, driven largely by a 14.6% smaller share count and a cyber-hit prior-year quarter, while US dialysis operating income grew just 2.9% as cost per treatment outpaced revenue per treatment.